Sosnowski Kellie, Mitchell Marion L, White Hayden, Morrison Lynette, Sutton Joanne, Sharratt Jessica, Lin Frances
1Intensive Care Unit, Logan Hospital, Logan City, Australia.
2Griffith University, Brisbane, Australia.
Pilot Feasibility Stud. 2018 Jan 11;4:32. doi: 10.1186/s40814-017-0224-x. eCollection 2018.
Early rehabilitation has been found to prevent delirium and weakness that can hamper the recovery of intensive care unit (ICU) survivors. Integrated clinical practice guidelines for managing patient pain, agitation and delirium (PAD) have been developed. The Awakening and Breathing Coordination, Delirium monitoring/management, and Early exercise/mobility (ABCDE) bundle provides a strategy to implement PAD guidelines into everyday clinical practice. However, there is limited evidence on the effectiveness of the ABCDE bundle in the literature.The purpose of this study was to evaluate the feasibility of conducting a full-scale randomised controlled trial comparing the ABCDE bundle to standard care in an ICU. Trial feasibility was defined as the successful recruitment and retention of trial participants, adherence to the intervention, identification of barriers to the intervention, and the rigorous collection of outcome data.
A prospective, single-centre, randomised controlled feasibility study was conducted. Thirty adult mechanically ventilated participants were recruited from an eight-bed ICU in south east Queensland, Australia, between April 2015 and December 2015. Participants were randomised to receive either the ABCDE bundle or standard routine management. The ABCDE bundle integrated prescribed awakening and breathing trials, delirium monitoring and management, and prescribed exercise and mobility regimes. Feasibility outcomes measured included recruitment and retention rates, intervention fidelity, and the feasibility of participant outcome data collection. Outcome measurement assessors were blinded to participant assignment. It was not possible to blind the research team or the participant to group assignment.
In total, 30 (81.1%) of 37 eligible participants consented and were randomised to the intervention group ( = 15) or the control group ( = 15). Of these, 23 (76.6%) participants successfully completed the 90-day post discharge assessment. A lengthy recruitment period of 8 months was related to overly stringent inclusion and exclusion criteria. Intervention adherence exceeded defined success rates with participation in awakening and breathing trials, delirium monitoring and exercise interventions performed on 80.2, 97.4 and 90.2% of ventilated days respectively. Outcome assessments were successfully and accurately performed at ICU and hospital discharge and 90-day post hospital discharge. Intervention participants were deemed to be delirious on 39.6% of mechanically ventilated days indicating a requirement for a scripted regime to prevent delirium.
With minor adjustment of inclusion and exclusion criteria, the inclusion of delirium management protocols, and encouragement of family engagement and involvement, a large-scale definitive randomised controlled trial to test the impact of the ABCDEF bundle will be feasible.
Australian New Zealand Clinical Trials Registry 12614000763640 Date registered 17/08/2014.
早期康复已被证实可预防谵妄和虚弱,而这些情况可能会妨碍重症监护病房(ICU)幸存者的康复。目前已制定了关于管理患者疼痛、躁动和谵妄(PAD)的综合临床实践指南。觉醒与呼吸协调、谵妄监测/管理以及早期运动/活动(ABCDE)集束化方案提供了一种将PAD指南应用于日常临床实践的策略。然而,文献中关于ABCDE集束化方案有效性的证据有限。本研究的目的是评估在ICU中开展一项将ABCDE集束化方案与标准护理进行比较的大规模随机对照试验的可行性。试验可行性定义为成功招募和保留试验参与者、依从干预措施、识别干预障碍以及严格收集结局数据。
进行了一项前瞻性、单中心、随机对照可行性研究。2015年4月至2015年12月期间,从澳大利亚昆士兰州东南部一个拥有8张床位的ICU招募了30名成年机械通气参与者。参与者被随机分配接受ABCDE集束化方案或标准常规管理。ABCDE集束化方案整合了规定的觉醒和呼吸试验、谵妄监测和管理以及规定的运动和活动方案。测量的可行性结局包括招募和保留率、干预保真度以及参与者结局数据收集的可行性。结局测量评估者对参与者的分组情况不知情。研究团队或参与者无法对分组情况不知情。
37名符合条件的参与者中,共有30名(81.1%)同意并被随机分配至干预组(n = 15)或对照组(n = 15)。其中,23名(76.6%)参与者成功完成了出院后90天的评估。长达8个月的招募期与过于严格的纳入和排除标准有关。干预依从性超过了规定的成功率,分别在80.2%、97.4%和90.2%的机械通气日进行了觉醒和呼吸试验、谵妄监测和运动干预。在ICU、出院时以及出院后90天成功且准确地进行了结局评估。干预组参与者在39.6%的机械通气日被判定为谵妄,这表明需要一个书面方案来预防谵妄。
对纳入和排除标准进行 minor调整,纳入谵妄管理方案,并鼓励家庭参与和介入,开展一项大规模的确定性随机对照试验以测试ABCDEF集束化方案的影响将是可行的。
澳大利亚新西兰临床试验注册中心12614000763640 注册日期2014年8月17日